Bonnie Anderson
Bonnie Anderson is co-founder, chair, and chief executive officer of PinkDx. She is a recognized leader in molecular diagnostics with a proven track record of translating genomic science into clinically adopted diagnostic tools. Prior to founding PinkDx, Anderson founded Veracyte where she served as president and chief executive officer, led the company from early development through commercialization, helped establish genomic diagnostics that reduced the need for invasive surgery, and changed clinical practice across multiple disease areas. She currently serves on multiple corporate and nonprofit boards and is widely recognized for advancing patient-centered innovation in diagnostics.
Giulia Kennedy, Ph.D.
Timothy McMeekan
Richard T. Kloos, M.D.
Giulia Kennedy, PhD, is co-founder and chief scientific officer of PinkDx. A molecular biologist and diagnostics innovator, she brings deep expertise in genomics, bioinformatics, and translational research. Prior to PinkDx, Kennedy was the chief scientific officer and chief medical officer of Veracyte, where she developed and validated genomic classifiers that enabled less invasive diagnostic pathways. At PinkDx, she leads scientific strategy and translational research focused on applying whole-transcriptome sequencing and machine learning in gynecologic cancer.
Timothy McMeekan is co-founder and chief financial and business officer of PinkDx. A veteran finance and operating executive, he brings 35 years of experience building, scaling, and transforming companies across life sciences, diagnostics, and premium consumer brands. He has built a reputation as an operator who can see around corners, modernize legacy businesses, and deliver market-shaping outcomes, pairing analytical discipline with customer-centric execution. At PinkDx, he leads financial strategy, business operations, and strategic partnerships to support clinical execution, operational scale, and long-term enterprise growth.
Richard T. Kloos, MD, is chief medical officer at PinkDx. A triple board-certified physician-researcher, he leads medical and clinical affairs to demonstrate the validity and utility of diagnostic tests, while guiding clinical strategy across the company’s pipeline. Prior to PinkDx, Kloos served as executive medical director at Veracyte, where he led a team of medical directors driving evidence generation and clinical adoption of treatment-altering diagnostic tests across multiple disease areas. He is the author of more than 135 peer-reviewed journal articles and book chapters and has contributed to clinical practice guidelines, including for the American Thyroid Association and The National Comprehensive Cancer Network, for more than a decade.